OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
K. Park(Samsung Medical Center), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Suzy Kim(The Catholic University of Korea Seoul St. Mary's Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Akira Inoue(Tohoku University Hospital), Hidetoshi Hayashi(Kindai University), Tomoki Nakagawa(Astellas Pharma (Japan)), Koichi Azuma(Kyushu University Hospital), Masashi Shimazaki(Tokyo Institute of Technology), Rio Akazawa(Astellas Pharma (Japan)), James Chih‐Hsin Yang(National Taiwan University Hospital), Katsuyuki Kiura(Okayama University Hospital), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Makoto Nishio(Japanese Foundation For Cancer Research), Chun‐Ming Tsai(Memorial Sloan Kettering Cancer Center), Satoshi Morita(Kyoto University), JiHoon Kang(Yale New Haven Hospital), Yoko Kaneko(Keio University), Koji Takeda(NewYork–Presbyterian Hospital), M. Fukuoka(Hyogo University of Health Sciences), Hiroshi Nokihara(Tokushima University Hospital)
Cited by 1
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k